Solara Active Pharma Sciences Limited (SOLARA) - Net Assets
Based on the latest financial reports, Solara Active Pharma Sciences Limited (SOLARA) has net assets worth Rs12.57 Billion INR (≈ $135.99 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs22.93 Billion ≈ $248.03 Million USD) and total liabilities (Rs10.36 Billion ≈ $112.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SOLARA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs12.57 Billion |
| % of Total Assets | 54.83% |
| Annual Growth Rate | 348.5% |
| 5-Year Change | -31.13% |
| 10-Year Change | N/A |
| Growth Volatility | 3793152.16 |
Solara Active Pharma Sciences Limited - Net Assets Trend (2017–2025)
This chart illustrates how Solara Active Pharma Sciences Limited's net assets have evolved over time, based on quarterly financial data. Also explore Solara Active Pharma Sciences Limited (SOLARA) total assets for the complete picture of this company's asset base.
Annual Net Assets for Solara Active Pharma Sciences Limited (2017–2025)
The table below shows the annual net assets of Solara Active Pharma Sciences Limited from 2017 to 2025. For live valuation and market cap data, see SOLARA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs10.97 Billion ≈ $118.63 Million |
+17.12% |
| 2024-03-31 | Rs9.37 Billion ≈ $101.29 Million |
-37.66% |
| 2023-03-31 | Rs15.02 Billion ≈ $162.49 Million |
-2.10% |
| 2022-03-31 | Rs15.35 Billion ≈ $165.98 Million |
-3.64% |
| 2021-03-31 | Rs15.93 Billion ≈ $172.25 Million |
+46.09% |
| 2020-03-31 | Rs10.90 Billion ≈ $117.90 Million |
+13.54% |
| 2019-03-31 | Rs9.60 Billion ≈ $103.85 Million |
+24.96% |
| 2018-03-31 | Rs7.68 Billion ≈ $83.11 Million |
+11469422.39% |
| 2017-03-31 | Rs67.00K ≈ $724.58 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Solara Active Pharma Sciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 315626700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs402.50 Million | 3.68% |
| Other Comprehensive Income | Rs9.60 Million | 0.09% |
| Other Components | Rs13.69 Billion | 125.08% |
| Total Equity | Rs10.94 Billion | 100.00% |
Solara Active Pharma Sciences Limited Competitors by Market Cap
The table below lists competitors of Solara Active Pharma Sciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Polaris Infrastructure Inc
TO:PIF
|
$193.99 Million |
|
Anterogen.Co.Ltd
KQ:065660
|
$194.04 Million |
|
Dynamic Cables Limited
NSE:DYCL
|
$194.13 Million |
|
AgriFORCE Growing Systems Ltd
NASDAQ:AGRI
|
$194.14 Million |
|
Michlol Finance Ltd
TA:MCLL
|
$193.91 Million |
|
Greenx Metals Ltd
AU:GRX
|
$193.85 Million |
|
India Nippon Electricals Limited
NSE:INDNIPPON
|
$193.77 Million |
|
Saksoft Limited
NSE:SAKSOFT
|
$193.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solara Active Pharma Sciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,339,100,000 to 10,942,400,000, a change of 1,603,300,000 (17.2%).
- Net income of 5,400,000 contributed positively to equity growth.
- Share repurchases of 1,590,200,000 reduced equity.
- New share issuances of 1,590,200,000 increased equity.
- Other comprehensive income increased equity by 15,599,999.
- Other factors increased equity by 1,582,300,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs5.40 Million | +0.05% |
| Share Repurchases | Rs1.59 Billion | -14.53% |
| Share Issuances | Rs1.59 Billion | +14.53% |
| Other Comprehensive Income | Rs15.60 Million | +0.14% |
| Other Changes | Rs1.58 Billion | +14.46% |
| Total Change | Rs- | 17.17% |
Book Value vs Market Value Analysis
This analysis compares Solara Active Pharma Sciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 82871.08x to 1.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | Rs0.01 | Rs495.80 | x |
| 2018-03-31 | Rs295.21 | Rs495.80 | x |
| 2019-03-31 | Rs386.56 | Rs495.80 | x |
| 2020-03-31 | Rs405.71 | Rs495.80 | x |
| 2021-03-31 | Rs462.97 | Rs495.80 | x |
| 2022-03-31 | Rs424.27 | Rs495.80 | x |
| 2023-03-31 | Rs416.77 | Rs495.80 | x |
| 2024-03-31 | Rs239.11 | Rs495.80 | x |
| 2025-03-31 | Rs283.70 | Rs495.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solara Active Pharma Sciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.04%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 2.04x
- Recent ROE (0.05%) is below the historical average (50019.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 450208.96% | 3.20% | 94127.80x | 1.49x | Rs301.63 Million |
| 2018 | 0.05% | 0.07% | 0.29x | 2.38x | Rs-760.21 Million |
| 2019 | 6.23% | 4.50% | 0.67x | 2.05x | Rs-360.60 Million |
| 2020 | 10.55% | 9.04% | 0.59x | 1.98x | Rs60.16 Million |
| 2021 | 13.94% | 13.87% | 0.61x | 1.65x | Rs625.48 Million |
| 2022 | -3.81% | -4.58% | 0.43x | 1.94x | Rs-2.11 Billion |
| 2023 | -1.48% | -1.55% | 0.49x | 1.93x | Rs-1.72 Billion |
| 2024 | -60.75% | -44.02% | 0.55x | 2.52x | Rs-6.61 Billion |
| 2025 | 0.05% | 0.04% | 0.58x | 2.04x | Rs-1.09 Billion |
Industry Comparison
This section compares Solara Active Pharma Sciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solara Active Pharma Sciences Limited (SOLARA) | Rs12.57 Billion | 450208.96% | 0.82x | $193.95 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arr… Read more